In the Review by Talasaz et al. (Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01003-3, 2024)¹, the authors comprehensively address the clinical challenge of balancing the reduction in the risk of cardiovascular events and the occurrence of spontaneous gastrointestinal bleeding (GIB) with the use of antithrombotic agents in patients with concurrent cardiovascular and gastrointestinal conditions. When discussing strategies to prevent GIB, the authors emphasize the importance of decreasing bleeding risk using proton pump inhibitors and risk stratification to individually tailor the antithrombotic therapy regimen. However, they only briefly touch on Helicobacter pylori infection as a risk factor for GIB. We believe that H. pylori infection warrants deeper scrutiny in patients with cardiovascular and gastrointestinal disease who are receiving antithrombotic agents.

在 Talasaz 等人的评论中。 （优化合并心血管和胃肠道疾病患者的抗血栓治疗。Nat . Rev. Cardiol。https ://doi.org/10.1038/s41569-024-01003-3, 2024） ¹ ，作者全面解决了平衡的临床挑战对于并发心血管和胃肠道疾病的患者，使用抗血栓药物可以降低心血管事件的风险和自发性胃肠道出血（GIB）的发生。在讨论预防 GIB 的策略时，作者强调了使用质子泵抑制剂降低出血风险和风险分层以单独定制抗血栓治疗方案的重要性。然而，他们只是简单地提到幽门螺杆菌感染是 GIB 的危险因素。我们认为，对于正在接受抗血栓药物治疗的心血管和胃肠道疾病患者，幽门螺杆菌感染值得进行更深入的检查。